AI Article Synopsis
Article Abstract
Nivolumab (Opdivo) is a monoclonal antibody classified as an immune modulator. A case is presented of nivolumab-induced myositis, an unlisted side effect.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153342 | PMC |
| http://dx.doi.org/10.1634/theoncologist.2016-0170 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-Kv1.4 Antibody-positive Nivolumab-induced Myasthenia Gravis and Myositis Presenting with Bilateral Ptosis and Demonstrating Different Pathophysiologies.
Intern Med
November 2023
Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan.
Nivolumab blocks inhibitors of T-cell activation and restores antitumor immunity but promotes T-cell activity in host tissues by blocking inhibition of the T-cell function, resulting in immune-related adverse effects. We herein report an 80-year-old man presenting with nivolumab-related myasthenia gravis with anti-muscular voltage-gated potassium channel-complex (Kv1.4) antibodies.
View Article and Find Full Text PDFClinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis.
Invest New Drugs
April 2023
Department of Pharmacy, The Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, YueLu District, 410013, Changsha, Hunan, China.
Background: To investigate the clinical features of nivolumab-induced myasthenia gravis (MG) and provide evidence for the rational use of nivolumab in the clinic.
Methods: We collected case reports and case series of nivolumab-induced MG for retrospective analysis by searching Chinese and English databases from 2014 to October 31, 2022.
Results: Of the 67 patients included, the median age was 72.
Nivolumab-induced Diaphragm Dysfunction: A Case Report.
Indian J Crit Care Med
February 2023
Department of Intensive Care Medicine, Amsterdam University Medical Centers, Amsterdam, North Holland, Netherlands.
Unlabelled: Nivolumab is increasingly used in the treatment of melanoma. However, its use is associated with potentially severe side effects and every organ system can be affected. A case is presented where nivolumab therapy resulted in severe diaphragm dysfunction.
View Article and Find Full Text PDFAnti-programmed death-1 inhibitor nivolumab-induced immune-related adverse events: hepatitis, renal insufficiency, myositis, vitiligo, and hypothyroidism: a case-based review.
Rheumatol Int
March 2023
Department of Pharmacology, Clinical Hospital Center Rijeka, Rijeka, Croatia.
Nivolumab (NIVO) is a monoclonal antibody used to treat renal cell cancer. It is an anti-programmed death-1 (anti-PD-1) inhibitor, enhancing the tumor-targeted immune response of T lymphocytes, resulting in immune-mediated adverse events (AEs). We present five immunological AEs in a single patient treated with NIVO.
View Article and Find Full Text PDFNivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody.
Intern Med
October 2022
Department of Medical Oncology, Matsudo City General Hospital, Japan.
Immune checkpoint inhibitors (ICIs) are complicated by immune-related adverse events (irAEs), such as myositis, myocarditis, and myasthenia gravis (MG). Anti-titin antibody and anti-voltage-gated potassium channel Kv1.4 antibody are anti-striated antibodies that are frequently detected in MG patients with myositis and/or myocarditis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!